|
 |
| home > ebr > Autumn 2001 |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR. |
 |
| |
|
|
| In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of the articles in this issue of EBR |
|
|
|
|
| Dr Francine Gervais, Vice-President of Research & Development at Neurochem Inc., examines Amyloid - Those Deadly Fibrils, expressing the hope that amyloid-related diseases will benefit from the successful clinical development achieved in amyloid disease-related drug programmes |
|
|
| Cancer is one of the major killers in the developed world, accounting for over one million deaths in North America and Europe annually. As it becomes clear that new therapies with better efficacy and specificity are urgently needed, Jean-Pierre Abastado, Vice-President, Scientific Affairs at IDM considers Dendritic Cells for Cancer Immunotherapy |
|
|
| In Putting Function First in Proteomics, Stefan Löfås, Vice President and Chief Scientific Officer at Biacore AB, describes how the last few years have seen an enormous revival in protein science and how SPR technology provides not only a means of isolating novel proteins, but also of uncovering their functional properties |
|
|
|
| A New Age for Biotechnology - 18th to 19th June 2001, London |
|
|
| Backström & Co Ltd. consider Biotechnology and Patents From the Finnish Point of View |
|
|
| Accentus - Meeting Your Contract Manufacturing Needs |
|
|
|
| In an interview with our Editor, Dr Helen Abbott, Taylor Crouch, CEO of Variagenics, Inc., considers the dawning of a brave new world as Personalised Medicine Draws Nearer |
|
|
|
| In Medicon Valley - The Scandinavian Hotspot, Ulf Åberg, Managing Director of Region Skåne, looks at how the area, with 54,000 people working within the medical industry, is rapidly emerging as one of Europe's dynamic centres of biotechnology and pharmaceutical development |
|
|
| As New York's State Government takes an aggressive approach to enhance bio-basedindustry growth in the region, Jeffrey Saelens, Manager of the Technology Information Unit; Keith Servis, Director for Programs; and Russell W Bessette, Executive Directorof NYSTAR, describe New York - The Biotechnology State: A New Renaissance |
|
|
|
| The market capitalisation of leading generics companies has increased during the last decade, and numerous changes in industry structure are expected to trigger continued growth. In The Emergence of Biogenerics, Klaus Maleck, Chief Financial Officer, and Federico Pollano, Head of Business Development at BioGeneriX AG, explain why investors have big hopes for the generics industry |
|
|
| Mario Johnson, Pharmaceutical Industry Manager for DHL International (UK) Ltd, highlights the fundamental changes that are reshaping the industry and addresses some of the challenges that it must face in Distribution of Temperature-Sensitive Products - When Time is More than Just Money |
|
|
| In Prion Safety of Biopharmaceuticals and Blood-Related Products, Melanie Dippel, Corporate Communications Manager at NewLab BioQuality AG, provides an overview of the subject of prion safety, the actions of international regulatory authorities, and the consequences for medicinal product manufacturers |
|
|
|
| The compilation, dissemination and use of databases containing human genetic information raise obvious data protection and privacy concerns. In a bid to identify ways of overcoming legislative obstacles, Myles Jelf, Associate, Bristows, poses the question, Data Protection - Can Anonymising Data Protect You? |
|
|
|
| In a world where chemistry is the key to a post-genomic future, forming the link between biological targets and drug development, Candace O'Connor, a Freelance Medical Journalist, explores Chemistry as Business in the New Chemo-Genomic Era |
|
|
| Dr Hermann Allgaier, Managing Director of Operations at LSMW GmbH, looks at Innovative Facility Concepts for Biopharmaceutical Multipurpose Pilot and Production Plants, explaining how varying manufacturing requirements strongly influence the design concept for pharmaceutical facilities |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
“PACK DIFFERENT” with EMBALLAGE 2008
“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >> |
|
__________________________
__________________________
__________________________
__________________________
|
